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Objective: To explore the genetic diversity and the modiﬁcation of antibody response in
the recent outbreak of Ebola Virus.
Methods: Sequences retrieved from public databases, the selective pressure analysis and
the homology modeling based on the all protein (nucleoprotein, VP35, VP40, soluble
glycoprotein, small soluble glycoprotein, VP30, VP24 and polymerase) were used.
Results: Structural proteins VP24, VP30, VP35 and VP40 showed relative conserved
sequences making them suitable target candidates for antiviral treatment. On the contrary,
nucleoprotein, polymerase and soluble glycoprotein have high mutation frequency.
Conclusions: Data from this study point out important aspects of Ebola virus sequence
variability that for epitope and vaccine design should be considered for appropriate tar-
geting of conserved protein regions.1. Introduction
Zaire Ebola virus (EBOV), a member of the Filoviridae family,
is a virulent Category A pathogen that causes considerable
morbidity and mortality. The EBOV genome is a linear, non-
segmented, single-stranded RNA approximately of 19 kb. The vi-
rus is ﬁlamentous and pleomorphic with a mean unit length of
1200 nm [1]. The viral genome encodes for a nucleoprotein (NP),
a glycoprotein (GP), a RNA dependent RNA polymerase (L),
and four structural proteins termed VP24, VP30, VP35 and VP40
[2–4]. The structural proteins, VP40 and VP24, represent viral
matrix proteins connecting the nucleocapsid to the viral envelope.
NP, VP30 and L proteins are of fundamental importance in the
replication and transcription of the Ebola genome [2,5]. The
envelope GP is an integral membrane protein, which forms spike-like protrusions on the surface of the virion. Recently, surface GP
level regulated by RNA editing mechanism has shown a funda-
mental role in EBOV pathogenicity and viral immune escape [6].
EBOV causes Ebola viral disease, characterized by fever,
malaise, and other nonspeciﬁc symptoms such as myalgia, head-
ache, vomiting, and diarrhea. About 30%–50% patients manifest
hemorrhagic symptoms. Moreover, in some severe cases multi-
organ dysfunction, including hepatic damage, renal failure, and
central nervous system involvement occur, leading to shock and
death [7]. ‘Cytokine storm’ with immune suppression of CD4 and
CD8 lymphocytes is a candidate mechanism for production of
the terminal hemorrhagic fever [8].
EBOV was ﬁrst identiﬁed in 1976 during the epidemic of
hemorrhagic fever in Zaire, now Democratic Republic of Congo,
with the epicenter of the outbreak in Yambuku. Zaire EBOV
appeared again in Democratic Republic of Congo in 1977 near
Yambuku and subsequent outbreaks among humans have occurred
in west-central Africa in distinct waves during 1994–1997 and
2001–2005 [9]. The recent and ongoing outbreak of EBOVDisease
began in December 2013 in forested areas of Southeastern Guinearticle under the CC BY-NC-ND license (http://
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Nigeria, and Sierra Leone. In Sierra Leone, a total of 8698
conﬁrmed cases with 3587 conﬁrmed deaths were reported in
the Ebola Situation Report of 2 September 2015, of which 302
(221 deaths) among health care workers [10,11]. A signiﬁcant
decline in both Ebola cases and deaths was observed until April
2015, although, sporadic outbreaks and deaths continue to occur,
including infection among health care workers [10]. In Africa,
EBOV disease infection have been documented through the
handling of infected chimpanzees, gorillas, fruit bats, monkeys,
forest antelope and porcupines found ill or dead or in the
rainforest. Ebola spreads to the community through person-to-
person transmission, with infection resulting from direct contact
with the blood, secretions, organs or other bodily ﬂuids, and indi-
rect contact with environments contaminated [12].
Although the knowledge of clinical and pathogenic aspects of
Ebola viral disease has recently improved the role of antibody
response in viral clearance and protection against EBOV in
humans is not fully understood. Fatal EBOV infection is charac-
terized by a defective innate immune response, leading to un-
controlled release of inﬂammatory mediators and chemokines in
the late stage of the disease, and correlates with the collapse of
adaptive immunity with massive T and B lymphocyte apoptosis.
Immune protection seems to be associated with the development
of both cellular and humoral immunity [13–17].
Several amino acid differences have been characterized in the
recent Ebola outbreak. A better knowledge of the viral protein
structure modiﬁcations represent the key point for drug design
and vaccination [18].
In this study, the selective pressure analysis was carried out
to detect the presence of sites under positive selective pressure
that could represent candidate ‘hot spot’ with a crucial rule in the
viral escape and evolution. Homology modeling analysis has
been performed to evaluate the virus evolution consequences in
the protein recognition by host immune response. We previously
performed these analyses considering only the contribution of
GP protein [18].
In this paper, the study is extended on all EBOV genome
transcripts to evaluate new targets for therapeutic and vaccine
strategies. Bioinformatics and immune-informatic approaches
can provide new insights into the pathogen's evolution, genetic
diversity and heterogeneity and the related protective immune
response against the virus to evaluate new targets for therapeutic
and vaccine strategies.
2. Materials and methods
2.1. Sequence data set and phylogenetic analysis
Seven different data set were built, one for each protein [NP,
VP35, VP40, soluble glycoprotein (sGP), VP30, VP24, L] down-
loading a number of sequences that ranged from 91 for NP and
VP40 proteins to 101 to sGP protein. The small soluble glyco-
protein (ssGP)was not investigated due to the fact that it is a portion
with the same reading frame of the GP, already described [19]. All
the sequenceswith known samplingdate and geographical location
were obtained from the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/).
The sampling dates for the sequences in the data set ranged from
1976 to 2014. All data sets were used to perform the selective
pressure and the homology modeling analysis. All the sequences
were aligned using ClustalX software and edited by using Bio-Editsoftware v. 7.0 [19], The best-ﬁtting nucleotide substitution models
were chosen with the hierarchical LRT strategy described by
Swofford & Sullivan [20], as implemented in the MODELTEST v.
3.7 program [21].
2.2. Selective pressure analysis
Comparison of relative ﬁxation rates of synonymous (silent)
and non-synonymous (amino acid-altering) mutations provide a
means for understanding the mechanisms of molecular sequence
evolution. The non-synonymous/synonymous rate ratio (u = dN/
dS) is an important indicator of selective pressure at the protein
level, with u = 1 meaning neutral mutations, u < 1 purifying
selection, and u > 1 diversifying positive selection.
The CODEML program implemented in the PAML 3.14
software package (http://abacus.gene.ucl.ac.uk/software/paml.
html) [22] was used to investigate the adaptive evolution of the
different data set of EBOV.
Six models of codon substitution: M0 (one-ratio), M1a (nearly
neutral), M2a (positive selection), M3 (discrete), M7 (beta), andM8
(beta and omega)were used in this analysis [23]. Since thesemodels
are nested, we used codon-substitution models to ﬁt the model to
the data using the likelihood ratio test (LRT) [24]. The M3 model,
with three dN/dS (u) classes, allows u to vary among sites by
deﬁning a set number of discrete site categories, each with its
own u value. Through maximum-likelihood optimization, it is
possible to estimate the u and P values and the fraction of sites in
the aligned data set that falls into a given category. Finally, the
algorithm calculates the a posteriori probability of each codon
belonging to a particular site category. Using the M3 model, sites
with a posterior probability exceeding 90% and a u value > 1.0
were designated as being ‘positive selection sites’ [23]. The site rate
variation was evaluated comparing M0 with M3, while positive
selection was evaluated comparing M1 with M2. The Bayes
empirical Bayes approach implemented in M2a and M8 was used
instead to determine the positively selected sites by calculating
the posterior probabilities of u classes for each site [25]. It is
worth noting that PAML LRTs have been reported to be
conservative for short sequences (e.g. positive selection could be
underestimated), although the Bayesian prediction of sites under
positive selection is largely unaffected by sequence length [25,26].
The dN/dS rate (u) was also estimated by the ML approach
implemented in the program HyPhy to enforce the previous
analysis [27]. Two different algorithms estimated site-speciﬁc
positive and negative selection: the ﬁxed effect likelihood and
random effect likelihood. The ﬁxed effect likelihood ﬁts au rate to
every site and uses the likelihood ratio to test if dN= dS. The random
effect likelihood is a variant of the Nielsen–Yang approach which
assumes that a discrete distribution of rates exists across sites and
allows both dS and dN to vary independently site by site. The three
methods have been described inmore detail elsewhere [28]. In order
to select sites under selective pressure and keep our test
conservative, a P value of 0.1 or a posterior probability of
0.9 as relaxed critical values was assumed.
For evolutionary analysis, the reference sequence Accession
Number: NC_002549 was used to trace the exact position of the
amino acids found under selection.
2.3. Amino acid mutation frequency analysis
Alignment between the Ebola protein reference sequences
derived from NC_002549 (NP: P18272, GP: Q05320, VP24:
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P60170, SSGP: Q9YMG2) and protein sequences of the new
Ebola epidemic have been performed evaluating all the amino
acid mutation frequencies and positions.
2.4. Homology modeling
The L protein has been excluded by the homology modeling
study because it consists of more than 2000 amino acid residue
and it cannot be modeled. Amino acid mutation with a frequency
lower than 0.1 has not been considered. A model of all the Ebola
protein, considering the sequences of the new epidemic, has
been generated using different homology modeling servers. The
servers have been tested using VP24 because its structure has
been already resolved. The obtained models have been
compared with VP24 crystallography structure (PDB ID:4M0Q)
and only the servers able to retrieve an RMSD  0.5 have been
chosen for further analyses.
Phyre2 server [29] showed the best performance combining
homology modeling and de novo modeling strategies in
comparison with other homology modeling servers such as
RaptorX, I-Tasser and SWISS-MODEL [30–32] GP protein
could not be properly modeled using the different servers.
Thus, loop modeling of the GP crystal structure in complex
with a neutralizing antibody has been performed (PDB ID:
3CSY). Loops modeling of GP to further perform sGP and
ssGP homology modeling experiments have been performed
on YASARA (Yet Another Scientiﬁc Artiﬁcial Reality
Application, http://www.yasara.com). All the resulting models
obtained have been ‘repaired’ to obtain best protein quality
and Alanine scanning has been performed using FoldX tools
implemented in YASARA as previously reported [33].
3. Results
3.1. Evolutionary analysis
Genetic variability was determined by nucleotide sequencing
of fragments ranging from 753 nt for the VP24 protein to
6 636 nt for the L protein. The Alfa parameter of the gamma
distribution for all the protein analyzed was <1, showing as thisTable 1
Likelihood values and parameters estimates for the selection analysis of the
Model code lnL dN/dS
VP40 M0 one ratio −1 862.86 0.190 u = 0.190
M1 neutral −1 853.89 0.150 P0 = 0.849 79, (P1
M2 selection −1 851.09 0.217 P0 = 0.968 37, P1 =
M3 discrete −1 851.11 0.217 P0 = 0.822 54, P1 =
u0 = 0.061 58, u1
M7 beta −1 854.43 0.200 P = 0.005 00 Q = 0
M8 beta and u −1 851.10 0.218 P0 = 0.968 76, (P1
u = 99.000 00
L-Pol M0 one ratio −10 899.72 0.089 u = 0.089 00
M1 neutral −10 893.33 0.089 P0 = 0.948 13, (P1
M2 selection −10 891.90 0.095 P0 = 0.997 01, P1 =
M3 discrete −10 891.97 0.095 P0 = 0.000 25, P1 =
u0 = 0.000 03, u1
M7 beta −10 893.69 0.091 P = 0.052 65 Q = 0
M8 beta and u −10 891.97 0.097 P0 = 0.997 18, (P1
u = 7.420 18distribution has a characteristic L-shape and suggesting a
nucleotide substitution rate heterogeneity across sites.
Likelihood values and parameter estimates obtained from
different data sets with site under selective pressure are listed in
Table 1. Estimates of the transition/transversion rate ratio (ts/tv)
are quite homogeneous among models in each data set and thus
are not shown in Table 1.
The average non-synonymous/synonymous substitution rate
ratio in VP40 protein ranges from 0.150 to 0.218 whereas in L
protein from 0.089 to 0.097. These values suggests that in VP40
protein non-synonymous mutation has about 15–22% much
chances as a synonymous mutation of being ﬁxed in the popu-
lation, whereas in L protein about from 9 to 10% for non-
synonymous mutation to be ﬁxed over time (Table 1).
Nevertheless having these proteins a u ratio <1, the purifying
selection dominates their evolution.
However, models that allow for positively selected sites (M2,
M3 and M8) signiﬁcantly ﬁt the data better that their counterpart
models for estimating neutral and negatively selected sites, as
suggested by the LRT (M1, M0 and M7 respectively). The
comparison between these models suggest the presence of
positively selected sites with a proportion of 3% for VP40
protein and a small percentage proportion (<1%) for L protein.
Two statistically supported sites, under positive selection,
each one with a probability >98%, respectively at amino acidic
position 247 (F, L); 324 (I, L, V) were found for VP40 protein.
Only one positive site, statistically supported, with a probability
>99% at amino acidic position 1610 (F, L), for the L, have been
found. Negative selected sites statistically supported, for all the
protein of EBOV ranged from 1% to 5.1% for VP35 and L, were
respectively found.3.2. Homology modeling strategy
L amino acid sequence has been analyzed; however, no
structure modeling has been performed because the protein has
more than 2000 amino acid residues. Of the overall 2 212 amino
acid positions, 53 sites are mutated (2.4%) and, among them, 24
have a frequency higher than 0.1. Structural proteins NP, VP35,
VP24, VP30 and glycoproteins sGP and ssGP have been
therefore analyzed for mutation frequency higher than 0.1 andVP40 and L-polymerase gene proteins.
Estimates of parameters Positively selected
sites
247 (F,L)
324 (I,L,V)= 0.150 21)
0.000 03 (P2 = 0.031 63) u2 = 0.061 60
0.145 82 (P2 = 0.031 64)
= 0.061 58, u2 = 4.996 09
.020 73
= 0.031 24), P = 6.652 79 Q = 99.000 00,
1 610 (F, L)
= 0.051 87)
0.000 02 (P2 = 0.002 99) u2 = 0.074 30
0.996 76 (P2 = 0.002 99)
= 0.074 38, u2 = 7.121 06
.521 07
= 0.002 82), P = 8.224 05 Q = 99.000 00,
Figure 1. Ebola protein modeled structure of NP and amino acid positions
with a mutation frequency higher than 0.1.
Six out of 340 amino acid positions are mutated in VP35 (1.8%). Among
them amino acid positions 12, 41, 68, and 204 have a mutation frequency
higher than 0.1 and alanine scanning results show that are all stabilizing
mutations (Figure 2 and Table 2).
Figure 2. Ebola protein modeled structure of VP35 and amino acid posi-
tions with a mutation frequency higher than 0.1.
Figure 4. Ebola protein modeled structure of VP24 and amino acid posi-
tions with a mutation frequency higher than 0.1.
Figure 5. Ebola protein modeled structure of VP40 and amino acid posi-
tions with a mutation frequency higher than 0.1.
Alba Grifoni et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(4): 337–343340for the consequences that each amino acid mutated positions
could induce on their structures (Figures 1–7 and Table 2).
NP mutation analysis shows that 32 out of 739 amino acid
residues (4.33%) are mutated. Among them 13 out of 32 mu-
tation have a frequency mutation higher than 0.1 (Figure 1). NP
mutation in amino acid position 8 is a destabilizing mutation,Figure 3. Ebola protein modeled structure of VP30 and amino acid posi-
tions with a mutation frequency higher than 0.1.
Figure 6. Ebola protein modeled structure of sGP and amino acid positions
with a mutation frequency higher than 0.1.while mutations in amino acid positions 11, 478, 517, 525, 527,
534, 708 are stabilizing mutations. Overall eight out thirteen
frequent mutations induce a conformational change in NP
structure (Table 2).
Structural proteins VP24 and VP30 have structures highly
conserved (Figures 3 and 4) with a low number of amino acid
mutated positions (VP24 = 0.8% and VP30 = 1.5%). None of the
amino acid mutations for each position have a frequency higher
than 0.1.
Figure 7. Ebola protein modeled structure of ssGP and amino acid posi-
tions with a mutation frequency higher than 0.1.
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structural protein (2.1%). Among them, amino acid positions 20
and 324 have a mutation frequency higher than 0.1. Alanine
scanning analysis shows a stabilizing mutation only in amino
acid position 324, which is located in the VP40 membrane-
binding region (Figure 5 and Table 2).
5.8% of mutated amino acid positions (21 out of 364), ﬁve of
them with a frequency higher than 0.1 as shown in Figure 6.
Speciﬁcally, amino acid positions 82, 262 and 314 are located inTable 2
Ebola proteins mutated amino acid positions.
Ebola
protein
Amino
acid
position
Reference Mutation Mutation
frequency
Alanine scan
DDG
(kCal/mol)
NP 8 I V 0.945054945 0.631 007
NP 11 A T 0.945054945 −1.946 6
NP 465 S G 0.736263736
NP 478 N S 0.736263736 −0.577 056
NP 517 I T 0.945054945 −0.862 761
NP 525 R T 0.736263736 −2.598 44
NP 527 I T 0.945054945 −0.658 525
NP 531 P T 0.736263736
NP 534 H R 0.846153846 −0.847 835
NP 631 T I 0.736263736
NP 644 S P 0.945054945
NP 708 E D 0.736263736 −0.922 518
NP 728 K R 0.736263736
VP35 12 A V 0.858695652 −4.061 62
VP35 41 S N 0.858695652 −2.001 55
VP35 68 T M 0.858695652 −1.650 1
VP35 204 N D 0.945652174 −2.273 44
VP40 20 V A 0.769230769
VP40 324 I V 0.823529412 −1.048 45
sGP 82 A V 0.455445545
sGP 262 T A 0.653465347
sGP 314 E D 0.514851485 −2.036 51
sGP 331 G R 0.653465347 3.873 55
sGP 336 L M 0.514851485 1.511 98
Amino acid positions with a mutation frequency higher than 0.1 and
relative Alanine scan values are shown. Destabilizing mutation are in
bold, stabilizing mutation are in italic. The DDG error margin is
approximately 0.5 kCal/mol, so changes in that range are insigniﬁcant
and have not been shown.the small-secreted GP portion, while amino acid positions 331
and 336 are located in the D-peptide. In addition, in amino acid
position 314 the mutation is stabilizing while only amino acid
positions 331 and 336 have destabilizing mutations (Table 2).
Due to sequence overlapping with GP1,2, ssGP mutation analysis
has been extracted by our previous results on GP [8]. Among
them, 6 out of 14 mutations have a frequency mutation higher
than 0.1 (Figure 7).
4. Discussion
Many factors may inﬂuence the circulation and the genetic
evolution of EBOV strains, including Virus infectivity, pre-
existing immunity in the population, and antigenic variability
of the virus. Antigenic variation, in particular, may play an
important role in the ability of these viruses to escape the human
immune response.
In this context, the analysis of the EBOV proteins gene
evolution is important not only because some of the protein are
an important target for the immune response during EBOV
infection, but also to better understand the evolutionary dynamic
of this virus.
This paper studied the evolution of EBOV proteins using ML
techniques. In this analysis only two of the analyzed proteins,
showed a high average ratio of non-synonymous to synonymous
nucleotide substitution (VP40 and L proteins) ranging from 0.08
to 0.22. As this value is not higher than the threshold of u > 1, is
therefore not indicative of positive selection [19]. Moreover, the
alpha parameter value was below 1, meaning that, most of the
sites along the gene may be invariable because they are under
strong purifying selection. A high proportion of amino acids
can be largely invariable, probably because amino acid
substitutions are not tolerated or selected for (i.e. strong
purifying selection). Because the average u seems usually not
sensitive enough to detect Darwinian selection at the
molecular level, we used in this case the codon substitution
models to detect sites under positive selection. By using these
methods, we have identiﬁed three sites under positive
selection in two different gene proteins (VP40 and L). These
results can indicates that although in these proteins a high
proportion of amino acids can be largely invariable probably
due at structural and functional constraints, adaptive evolution
may occur at certain sites of the genome. On the contrary,
several amino acid differences have been characterized in the
recent Ebola outbreak in EBOV G glycoprotein [18]. A better
knowledge of the viral protein structure modiﬁcations is the
key point for drug design and vaccination. Beside the fact that
different studies have been focusing on Ebola GP, also VP24
VP30 VP35 and VP40 structural proteins have been recently
investigated as potential drug targets [34–37]. Therefore, the
evaluation of the genetic heterogeneity in these proteins
assumes an increased importance not only in the viral immune
escape but also in the drug design. In this study, structural
proteins VP24, VP30, VP35 and VP40 show relatively
conserved sequences making them suitable target candidates
for antiviral treatment as previously suggested [36,37]. On the
contrary, NP, L and soluble GP have high mutation frequency.
In this context, NP and GP have been chosen as vaccine
candidates and for antibody epitopes design as they are the
most abundant protein in the infected cells [38–41], but with the
frequency of mutation that characterized them attention should
be used in the target region.
Alba Grifoni et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(4): 337–343342In conclusion, this study pointed out important aspects of
EBOV sequence variability that for epitope and vaccine design
should be taken in consideration for appropriate targeting of
conserved protein regions.
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